William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024. This is a modal window. The Playback API request failed for an ...
However, currently there are no standardized diagnostic or therapeutic guidelines for TCM management of emotional disturbances accompanying breast cancer. This guideline, authored by a panel of experts in the field of TCM, including specialists in breast oncology, breast surgery, and psychosomatic ...
[5]NCCN Guidelines Version 3.2023 Breast Cancer [6]Moy B, Rumble RB, Come SE, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update...
1. Guideline principles 2. Principles for disease assessment of advanced breast cancer 3. Principles for ABC treatment 4. Treatment of unresectable locally advanced breast cancer 5. General principles of chemotherapy for ABC 6. Treatment for HR+ and HER2- ABC 7. Treatment for HER2-positive ABC ...
Clinical Practice Guideline Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024 Jianbin Li,Chunfang Hao,Kun Wang,Jian Zhang,Jiayi Chen,Yueping Liu,Jianyun Nie,Min Yan,Qiang Liu,Cuizhi Geng,Xiaojia Wang,Haibo Wang,Shusen Wang,Jiong Wu,Yongmei Yin,Erwei Song,Zefei Jiang ...
[5] G Curigliano, L Castelo-Branco, A Gennari, et al. ESMO Metastatic Breast Cancer Living Guideline. Ann Oncol 2021;32(12): 1475-1495, ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. 王坤 教授 广东省人民医院肿瘤医院副院长、博士研究生导师 ...
[5]G Curigliano, L Castelo-Branco, A Gennari, et al. ESMO Metastatic Breast Cancer Living Guideline. Ann Oncol 2021;32(12): 1475-1495, ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. 王坤 教授 广东省人民医院肿瘤医院副院长、博士研究生导师 ...
[5]NCCN Guidelines Version 3.2023 Breast Cancer [6]Moy B, Rumble RB, Come SE, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update...
[2] Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867-3872. [3] ...
[5]Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867-3872. [6]...